U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06800066) titled 'RCT-Consumer Perceptions of Cannabidiol (CBD) Health Claims' on Jan. 06.
Brief Summary: Cannabidiol (CBD) cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been illicitly advertised to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer and preventing Alzheimer's disease. These ty...